PSEN2 Presenilin 2 AD Causal Chain

PSEN2 Presenilin 2 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN2 (Presenilin 2) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points. PSEN2 is the second causative gene for familial Alzheimer's disease and provides unique insights into gamma-secretase biology and disease heterogeneity.

Genetic Evidence

PSEN2 Gene Overview

PSEN2 encodes Presenilin 2, the catalytic subunit of the gamma-secretase complex. While less frequently mutated than PSEN1, PSEN2 mutations cause both familial and potentially sporadic Alzheimer's disease.

| Property | Value |
|----------|-------|
| Chromosome | 1q42.13 |
| Protein | Presenilin 2 (448 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 55-75 years (mean ~65) |

Key Pathogenic Mutations

Over 70 pathogenic mutations in PSEN2 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Population |
|----------|----------|--------|-------------|
| N141I | TM2 | Severe Aβ42 increase, reduced activity | Volga German |
| M239V | TM6 | Increased Aβ42/Aβ40 ratio | Italian |
| T122P | TM4 | Impaired gamma-secretase | German |
| M239I | TM6 | Altered APP processing | - |
| A85V | TM2 | Partial loss of function | - |
| R62H | TM1 | Reduced proteolytic activity | - |

Genetic Evidence Score: 10/10

PSEN2 Presenilin 2 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN2 (Presenilin 2) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points. PSEN2 is the second causative gene for familial Alzheimer's disease and provides unique insights into gamma-secretase biology and disease heterogeneity.

Genetic Evidence

PSEN2 Gene Overview

PSEN2 encodes Presenilin 2, the catalytic subunit of the gamma-secretase complex. While less frequently mutated than PSEN1, PSEN2 mutations cause both familial and potentially sporadic Alzheimer's disease.

| Property | Value |
|----------|-------|
| Chromosome | 1q42.13 |
| Protein | Presenilin 2 (448 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 55-75 years (mean ~65) |

Key Pathogenic Mutations

Over 70 pathogenic mutations in PSEN2 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Population |
|----------|----------|--------|-------------|
| N141I | TM2 | Severe Aβ42 increase, reduced activity | Volga German |
| M239V | TM6 | Increased Aβ42/Aβ40 ratio | Italian |
| T122P | TM4 | Impaired gamma-secretase | German |
| M239I | TM6 | Altered APP processing | - |
| A85V | TM2 | Partial loss of function | - |
| R62H | TM1 | Reduced proteolytic activity | - |

Genetic Evidence Score: 10/10

• Causality strength: Absolutely proven - PSEN2 mutations are fully penetrant causes of familial AD
• Population frequency: Very rare (<0.001% of population)
• Age of onset: Later than PSEN1 (~65 years average), consistent with "late-onset" FAD
• Segregation: Perfect Mendelian inheritance in affected families
• Unique feature: Some PSEN2 mutations show incomplete penetrance or variable expressivity

Molecular Mechanism

Gamma-Secretase Complex

PSEN2 functions as the catalytic core of the gamma-secretase complex, similar to PSEN1 but with distinct biochemical properties:

Distinct Properties of PSEN2-Containing Complexes

PSEN2-containing γ-42 complexes differ from PSEN1 complexes in several ways:

Amyloid Beta Production Pathway

PSEN2 mutations alter gamma-secretase cleavage through multiple mechanisms:

Downstream Molecular Effects

Cellular Mechanisms

Mitochondrial Dysfunction

PSEN2 has unique roles in mitochondrial biology not shared with PSEN1:

Autophagy and Lysosomal Dysfunction

PSEN2 mutations impair autophagy through multiple mechanisms:

• Autophagosome accumulation - Reduced fusion with lysosomes
• Lysosomal acidification defect - Impaired protease activity
• TFEB nuclear translocation - Reduced autophagy gene expression
• mTORC1 dysregulation - Altered nutrient sensing

Synaptic Dysfunction

PSEN2 mutations contribute to synaptic failure through:

• Aβ-induced LTP impairment - Memory trace weakening
• Calcium dysregulation - ER calcium leak through mutant presenilin
• Synaptic protein trafficking - Altered delivery to synapses
• Mitochondrial energy deficit - Insufficient ATP for synaptic function

Clinical Phenotype

Disease Progression

| Stage | Age | Clinical Features |
|-------|-----|-------------------|
| Preclinical | 55-60 | Normal cognition, biomarker changes (elevated Aβ42, tau) |
| Prodromal | 60-65 | MCI, episodic memory deficits |
| Mild AD | 65-70 | Working memory impairment, word-finding difficulty |
| Moderate AD | 70-75 | Disorientation, behavioral changes |
| Severe AD | 75+ | Global cognitive decline, motor symptoms |

Phenotypic Heterogeneity

PSEN2 mutations show distinct clinical features from PSEN1:

• Later age of onset - Average ~65 years vs ~45 years for PSEN1
• Atypical presentations - Some mutations cause spastic paraparesis
• Variable penetrance - Some PSEN2 mutations show incomplete penetrance
• Pathology diversity - Some cases show Lewy body co-pathology
• Psychiatric symptoms - Higher frequency of depression and psychosis

Comparison with PSEN1

| Feature | PSEN1 | PSEN2 |
|---------|-------|-------|
| Age of onset | 30-60 years | 55-75 years |
| Disease duration | 8-12 years | 10-15 years |
| Myoclonus/seizures | Common | Less common |
| Spastic paraparesis | Rare | Some mutations |
| Atypical features | Less common | More common |

Therapeutic Intervention Points

Current Therapeutic Strategies

| Intervention | Mechanism | Development Stage | Target |
|--------------|-----------|-------------------|--------|
| Gamma-secretase modulators (GSMs) | Shift cleavage to less Aβ42 | Phase 2/3 | Aβ42 production |
| Anti-Aβ antibodies | Passive immunization | Phase 3 (lecanemab, donanemab) | Aβ plaques |
| Aβ oligomer inhibitors | Block toxic oligomers | Preclinical | Aβ42 oligomers |
| Notch-sparing inhibitors | Reduce Notch side effects | Preclinical | γ-secretase |
| PSEN2-selective modulators | Target PSEN2 complexes | Preclinical | PSEN2-γ42 |

PSEN2-Specific Considerations

Gene-Specific Therapies

| Approach | Strategy | Challenges | Timeline |
|----------|----------|------------|----------|
| ASO therapy | Silence mutant PSEN2 | Allele-specific targeting | 5-10 years |
| CRISPR-Cas9 | Correct mutation | CNS delivery, efficiency | 10+ years |
| Protein folding drugs | Correct PSEN2 misfolding | Brain delivery | 5-10 years |
| Mitochondrial protectants | Restore mitochondrial function | Target mitochondria | 3-7 years |

Intervention Point Diagram

Evidence Scores

| Category | Score | Rationale |
|----------|-------|-----------|
| Genetic Causality | 10/10 | Fully penetrant, autosomal dominant, >70 mutations identified |
| Mechanism Validation | 9/10 | Gamma-secretase complex well-characterized, distinct PSEN2 properties |
| Therapeutic Potential | 7/10 | Multiple approaches in development; later onset provides longer window |
| Clinical Translation | 7/10 | Biomarkers available but less clinical trial data than PSEN1 |
| Overall | 8.25/10 | Strong evidence for causal chain with unique features |

Cross-Disease Synthesis

Alzheimer's Disease Subtypes

• Late-onset familial AD: PSEN2 accounts for ~5-10% of FAD cases
• Sporadic AD modifier: PSEN2 variants may modify risk in LOAD
• Atypical AD: Some PSEN2 mutations cause posterior cortical atrophy or spastic paraparesis

Cross-Disease Connections

| Disease | Connection | Evidence |
|---------|------------|----------|
| Parkinson's Disease | PSEN2 affects alpha-synuclein processing; mitochondrial complex I | Moderate |
| FTD | TDP-43 co-pathology in some cases | Weak-Moderate |
| ALS | Shared neuroinflammation pathways | Weak |
| Cerebral amyloid angiopathy | Aβ42 vascular deposition | Strong |

Shared Mechanisms with Other Neurodegeneration

• Protein aggregation - Similar to α-synuclein (PD), TDP-43 (ALS)
• Mitochondrial dysfunction - Universal feature across neurodegenerative diseases
• ER stress - Shared with ALS (C9orf72, SOD1)
• Autophagy impairment - Common across AD, PD, ALS

PSEN1 vs PSEN2 Comparison

| Feature | PSEN1 | PSEN2 |
|---------|-------|-------|
| Mutation count | 300+ | 70+ |
| Age of onset | 30-60 years | 55-75 years |
| Expression pattern | Ubiquitous | More restricted |
| Aβ profile | Aβ42 ↑↑ | Aβ42/Aβ43 ↑ |
| Mitochondrial role | Less prominent | Prominent |
| Notch processing | Primary | Secondary |

Knowledge Gaps and Research Priorities

Unresolved Questions

High-Priority Research Areas

| Priority | Research Area | Rationale |
|----------|---------------|-----------|
| 1 | PSEN2-selective GSMs | Target PSEN2-containing complexes specifically |
| 2 | Mitochondrial protectants | Exploit unique PSEN2 mitochondrial roles |
| 3 | Biomarker development | Earlier detection in PSEN2 carriers |
| 4 | Gene therapy | Direct correction of pathogenic mutations |

References